1077 related articles for article (PubMed ID: 28128575)
1. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
[TBL] [Abstract][Full Text] [Related]
2. [Severe familial hypercholesterolemia treatment].
Vrablík M; Freiberger T; Bláha V; Češka R
Vnitr Lek; 2016; 62(11):895-901. PubMed ID: 28128576
[TBL] [Abstract][Full Text] [Related]
3. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
Aljenedil S; Ruel I; Watters K; Genest J
J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
[TBL] [Abstract][Full Text] [Related]
4. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
5. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
6. Familial hypercholesterolemia treatments: Guidelines and new therapies.
Raal FJ; Hovingh GK; Catapano AL
Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
[TBL] [Abstract][Full Text] [Related]
7. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
8. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
Miname MH; Santos RD
Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
[TBL] [Abstract][Full Text] [Related]
9. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Robinson JG
J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
[TBL] [Abstract][Full Text] [Related]
10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
11. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
[TBL] [Abstract][Full Text] [Related]
12. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
13. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
Bell DA; Hooper AJ; Watts GF; Burnett JR
Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
[TBL] [Abstract][Full Text] [Related]
14. Modern Management of Familial Hypercholesterolemia.
Duell PB; Jialal I
Metab Syndr Relat Disord; 2016 Dec; 14(10):463-467. PubMed ID: 27797643
[TBL] [Abstract][Full Text] [Related]
15. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
[TBL] [Abstract][Full Text] [Related]
16. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
[TBL] [Abstract][Full Text] [Related]
17. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
Schaefer JR; Kurt B; Sattler A; Klaus G; Soufi M
Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):2-6. PubMed ID: 22528129
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
20. [How to deal ugly twins, LDL-cholesterol and lipoprotein (a)].
Piťha J
Vnitr Lek; 2016; 62(11):903-907. PubMed ID: 28128577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
